Page 8 - Andy Hsieh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Andy hsieh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Andy Hsieh Today - Breaking & Trending Today

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate. ....

New Jersey , United States , William Blair , Andy Hsieh , Jacob Van Naarden , Novartis Lutathera , Eli Lilly , Point Biopharma Global , Van Naarden , Point Theranostics , Mariana Oncology , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company ,

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest - Exelixis (NASDAQ:EXEL)

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was  ....

Andy Hsieh , Exelixis Inc , William Bliar , William Blair , Alexandra Ramsey , Alliance For Clinical Trials In Oncology , Clinical Trials , Safety Monitoring Board ,

Analyst Downgrades Aravive: Grapples With Trial Setback, Strategic Alternatives - Aravive (NASDAQ:ARAV)

Monday, Aravive Inc (NASDAQ: ARAV) filed its quarterly 10Q ....

Andy Hsieh , William Blair , Alexandra Ramsey , Cantor Fitzgerald , Aravive Inc , Clear Cell Renal Carcinoma ,

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients - Roche Holding (OTC:RHHBF), Ipsen (OTC:IPSEF), Roche Holding (OTC:RHHVF), Exelixis (NASDAQ:EXEL), Ipsen (OTC:IPSEY), Roche Holding (OTC:RHHBY)

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs ....

Alexandra Ramsey , Andy Hsieh , Exelixis Inc , William Blair , Roche Holdings ,

Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market - Seagen (NASDAQ:SGEN)

Earlier today, Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) met its primary endpoint of  ....

Andy Hsieh , Alexandra Ramsey , Seagen Inc , William Blair , Pfizer Inc , European Society For Medical Oncology , European Society ,